Swedish biopharma company BioArctic AB (BIOA_B.ST,BIOA-B.ST,BRCTF) said that its partner Eisai has launched Leqembi in Austria on Monday, with the launch in Germany planned on September 1.
BioArctic said that Leqembi, approved by the European Commission in April this year, is the first European Union-approved therapy targeting an underlying cause of the Alzheimer's disease. It is indicated for adults with early Alzheimer's, MCI or mild dementia, who are ApoE e4 non-carriers or heterozygotes with confirmed amyloid pathology.
The company said that Austria and Germany are the first European Union markets to offer the treatment.
Following EC approval, Eisai worked in collaboration with healthcare authorities to meet mandatory authorization requirements, including a controlled access program now in place in both countries.
According to BioArctic, Leqembi stems from its research based on Professor Lars Lannfelt's discovery of the Arctic mutation. BioArctic and Eisai have a long-standing partnership, with Eisai leading global development, approvals, and commercialization, while BioArctic retains rights to co-commercialize the therapy in the Nordic region.
Alzheimer's disease is a progressive neurodegenerative condition marked by amyloid-beta and tau pathology, advancing in stages that pose increasing challenges for patients.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.